MCID: LRG008
MIFTS: 50

Large Granular Lymphocyte Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Large Granular Lymphocyte Leukemia

MalaCards integrated aliases for Large Granular Lymphocyte Leukemia:

Name: Large Granular Lymphocyte Leukemia 53
T-Cell Large Granular Lymphocyte Leukemia 53 73
Leukemia, Large Granular Lymphocytic 73
Lgl Leukemia 53

Classifications:



External Ids:

Summaries for Large Granular Lymphocyte Leukemia

NIH Rare Diseases : 53 Large granular lymphocyte (LGL) leukemia is a rare cancer of a type of white blood cells called lymphocytes. LGL leukemia causes a slow increase in white blood cells called T lymphocytes, or T cells, which originate in the lymph system and bone marrow and help to fight infection. This disease usually affects people in their sixties. Symptoms include anemia; low levels of platelets (thrombocytopenia) and infection-fighting neutrophils (neutropenia) in the blood; and an enlarged spleen. About one-third of patients are asymptomatic at the time of diagnosis. The exact cause of LGL leukemia is unknown. Doctors can diagnose this disease through a bone marrow biopsy, or by using a specialized technique in which various types of blood or bone marrow cells are separated, identified, and counted.

MalaCards based summary : Large Granular Lymphocyte Leukemia, also known as t-cell large granular lymphocyte leukemia, is related to t-cell large granular lymphocyte leukemia and pure red-cell aplasia. An important gene associated with Large Granular Lymphocyte Leukemia is STAT3 (Signal Transducer And Activator Of Transcription 3), and among its related pathways/superpathways are PEDF Induced Signaling and Akt Signaling. The drugs Ketamine and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Related Diseases for Large Granular Lymphocyte Leukemia

Diseases related to Large Granular Lymphocyte Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 144)
# Related Disease Score Top Affiliating Genes
1 t-cell large granular lymphocyte leukemia 34.3 STAT3 STAT5B
2 pure red-cell aplasia 30.9 IL2RA STAT3
3 chronic graft versus host disease 29.8 IFNG IL2RA
4 rheumatoid arthritis 29.8 CSF2 IFNG IL2RA
5 aspergillosis 29.7 CSF2 IFNG
6 aplastic anemia 29.6 CSF2 IFNG STAT3
7 autoimmune disease 29.5 IFNG IL2RA STAT3
8 natural killer cell leukemia 11.9
9 leukemia 11.1
10 lymphocytic leukemia 10.9
11 lymphoma 10.5
12 arthritis 10.4
13 neutropenia 10.4
14 hemolytic anemia 10.3
15 autoimmune lymphoproliferative syndrome, type v 10.3
16 viral infectious disease 10.3
17 hepatosplenic t-cell lymphoma 10.3
18 felty syndrome 10.2
19 anemia, autoimmune hemolytic 10.2
20 b-cell lymphomas 10.2
21 heavy chain disease 10.2
22 gamma heavy chain disease 10.2
23 prolymphocytic leukemia 10.2
24 t-cell leukemia 10.2
25 myelodysplastic syndrome 10.1
26 hematopoietic stem cell transplantation 10.1
27 hepatitis 10.1
28 lymphomatoid granulomatosis 10.1
29 hairy cell leukemia 10.1
30 purpura 10.1
31 neuropathy 10.1
32 chronic active epstein-barr virus infection 10.1
33 splenomegaly 10.1
34 t-cell prolymphocytic leukemia 10.1
35 autoimmune enteropathy 10.1 IL2RA STAT3
36 anemia of prematurity 10.1 CSF2 STAT5B
37 myeloproliferative neoplasm 10.1 STAT3 STAT5B
38 head injury 10.0 IL2RA LBR
39 suppurative lymphadenitis 10.0 IFNG STAT3
40 lymphadenitis 10.0 IFNG STAT3
41 hyper ige syndrome 10.0 IFNG STAT3
42 myeloma, multiple 10.0
43 thymoma 10.0
44 vasculitis 10.0
45 interferon gamma, receptor 1, deficiency 10.0 IFNG LBR
46 trichosporonosis 10.0 CSF2 IFNG
47 mucormycosis 10.0 CSF2 IFNG
48 candida glabrata 9.9 CSF2 IFNG
49 leukemia, chronic lymphocytic 2 9.9
50 hepatocellular carcinoma 9.9

Graphical network of the top 20 diseases related to Large Granular Lymphocyte Leukemia:



Diseases related to Large Granular Lymphocyte Leukemia

Symptoms & Phenotypes for Large Granular Lymphocyte Leukemia

MGI Mouse Phenotypes related to Large Granular Lymphocyte Leukemia:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.95 CSF2 IFNG IL2RA LBR STAT3 STAT5B
2 growth/size/body region MP:0005378 9.93 CSF2 IFNG IL2RA LBR STAT3 STAT5B
3 hematopoietic system MP:0005397 9.91 CSF2 IFNG IL2RA LBR STAT3 STAT5B
4 homeostasis/metabolism MP:0005376 9.88 CSF2 IFNG IL2RA LBR STAT3 STAT5B
5 immune system MP:0005387 9.85 CSF2 IFNG IL2RA LBR STAT3 STAT5B
6 adipose tissue MP:0005375 9.83 CSF2 LBR STAT3 STAT5B
7 craniofacial MP:0005382 9.81 CSF2 IFNG LBR STAT3
8 digestive/alimentary MP:0005381 9.8 IFNG IL2RA LBR STAT3
9 mortality/aging MP:0010768 9.73 CSF2 IFNG IL2RA LBR STAT3 STAT5B
10 integument MP:0010771 9.72 CSF2 IFNG LBR STAT3 STAT5B
11 renal/urinary system MP:0005367 9.55 CSF2 IFNG LBR STAT3 STAT5B
12 reproductive system MP:0005389 9.35 CSF2 IFNG LBR STAT3 STAT5B
13 respiratory system MP:0005388 9.02 CSF2 IFNG IL2RA LBR STAT3

Drugs & Therapeutics for Large Granular Lymphocyte Leukemia

Drugs for Large Granular Lymphocyte Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 237)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
3
Ofloxacin Approved Phase 3 82419-36-1 4583
4
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
5
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
6
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
7
Iron Approved Phase 3,Phase 1,Phase 2,Not Applicable 7439-89-6 23925
8
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 772 46507594
11
Dalteparin Approved Phase 3 9005-49-6
12
Ondansetron Approved Phase 3,Not Applicable 99614-02-5 4595
13
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
14
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
15
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
16
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 93-14-1 3516
17
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
18
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
19
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
20
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
21
Busulfan Approved, Investigational Phase 2, Phase 3,Early Phase 1 55-98-1 2478
22
Etoposide Approved Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
23
Melphalan Approved Phase 2, Phase 3,Not Applicable 148-82-3 4053 460612
24
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
25 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
26 Anesthetics, Dissociative Phase 3
27 Anesthetics, General Phase 3
28 Excitatory Amino Acid Antagonists Phase 3
29 Excitatory Amino Acids Phase 3
30 Central Nervous System Depressants Phase 3,Phase 1,Phase 2,Not Applicable
31 Analgesics Phase 3,Phase 2,Not Applicable
32 Anesthetics, Intravenous Phase 3
33 Neurotransmitter Agents Phase 3,Not Applicable
34 Anesthetics Phase 3
35 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Renal Agents Phase 3,Phase 1,Phase 2
38 Cephalosporins Phase 3
39 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1,Phase 2,Not Applicable
40 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Anti-Infective Agents, Urinary Phase 3,Phase 1,Phase 2
42 Cytochrome P-450 CYP1A2 Inhibitors Phase 3,Not Applicable
43 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Cola Phase 3,Phase 1,Phase 2
45 Immunosuppressive Agents Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1
46 Alkylating Agents Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable
47 Immunologic Factors Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable
49 Antirheumatic Agents Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Narcotics Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 126)
# Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
3 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
4 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
5 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
6 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
9 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
10 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
11 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
12 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
13 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
14 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
15 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
16 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
17 Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer Completed NCT00031980 Phase 2 cyclosporine
18 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents Completed NCT00003635 Phase 2 nelarabine
19 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
20 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
21 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
22 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
23 Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Completed NCT00278213 Phase 2 cyclophosphamide;fludarabine phosphate;mitoxantrone hydrochloride
24 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
25 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
26 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
27 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
28 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
29 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
30 Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer Completed NCT00006225 Phase 1, Phase 2
31 Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia Recruiting NCT01976182 Phase 2 Methotrexate;Cyclophosphamide
32 A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL Recruiting NCT03239392 Phase 1, Phase 2 BNZ132-1-40
33 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
34 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
35 Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies Recruiting NCT00002663 Phase 1, Phase 2
36 Alemtuzumab (Campath ) to Treat T-Large Granular Lymphocyte Leukemia Active, not recruiting NCT00345345 Phase 2
37 Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Active, not recruiting NCT01643603 Phase 1, Phase 2 Dasatinib
38 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01839916 Phase 2
39 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
40 Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting NCT00104858 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
41 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
42 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Active, not recruiting NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
43 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies Active, not recruiting NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
44 Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Active, not recruiting NCT01609816 Phase 1, Phase 2 Dasatinib
45 Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia Terminated NCT00363779 Phase 2 Cyclosporine
46 Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia Terminated NCT00278265 Phase 2 MTX followed by fludarabine
47 Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia Terminated NCT00360776 Phase 2 tipifarnib
48 Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL) Terminated NCT01191749 Phase 2 Alemtuzumab
49 Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer Terminated NCT01769222 Phase 1, Phase 2
50 Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant Terminated NCT01419795 Phase 2 lenalidomide

Search NIH Clinical Center for Large Granular Lymphocyte Leukemia

Genetic Tests for Large Granular Lymphocyte Leukemia

Anatomical Context for Large Granular Lymphocyte Leukemia

MalaCards organs/tissues related to Large Granular Lymphocyte Leukemia:

41
T Cells, Bone, Bone Marrow, Spleen, Neutrophil, Myeloid, Nk Cells

Publications for Large Granular Lymphocyte Leukemia

Articles related to Large Granular Lymphocyte Leukemia:

(show top 50) (show all 199)
# Title Authors Year
1
Dysfunction of immune system in the development of large granular lymphocyte leukemia. ( 30334691 )
2019
2
Complete remission of agranulocytosis after splenectomy in a variant formA of T-cell large granular lymphocyte leukemia. ( 29963929 )
2018
3
Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders. ( 29473430 )
2018
4
Dysregulation of the IFN-I^-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. ( 29474442 )
2018
5
Somatic<i>STAT3</i>mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia. ( 29217783 )
2018
6
Donor derived T-cell large granular lymphocyte leukemia after cord blood transplant for pediatric T-cell lymphoblastic leukemia. ( 29269802 )
2018
7
Management of T-cell large granular lymphocyte leukemia and concurrent retroperitoneal liposarcoma. ( 30057739 )
2018
8
Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach. ( 28167832 )
2017
9
Dysregulated signaling, proliferation and apoptosis impact on the pathogenesis of TCRγδ+ T cell large granular lymphocyte leukemia. ( 28407008 )
2017
10
High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. ( 27697773 )
2016
11
Single-center Series of Bone Marrow Biopsy-Defined Large Granular Lymphocyte Leukemia: High Rates of Sustained Response to Oral Methotrexate. ( 27640075 )
2016
12
Cell size variations of large granular lymphocyte leukemia: Implication of a small cell subtype of granular lymphocyte leukemia with STAT3 mutations. ( 27064362 )
2016
13
Population-based analyses among 184 patients diagnosed with large granular lymphocyte leukemia in the Netherlands between 2001 and 2013. ( 27055870 )
2016
14
A population-based study of large granular lymphocyte leukemia. ( 27494824 )
2016
15
Prolonged complete hematologic response in relapsed/refractory T-large granular lymphocyte leukemia after bendamustine treatment. ( 27896231 )
2016
16
Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation. ( 26460210 )
2015
17
Hepatic Lesions Caused by Large Granular Lymphocyte Leukemia in Fischer 344 Rats: Similar Morphologic Features and Morphogenesis to Those of Nodular Regenerative Hyperplasia (NRH) in the Human Liver. ( 25903270 )
2015
18
Good syndrome presenting with CD8+ T-Cell large granular lymphocyte leukemia. ( 26429871 )
2015
19
Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia. ( 26252351 )
2015
20
High rate of both hematopoietic and solid tumors associated with large granular lymphocyte leukemia. ( 24882263 )
2014
21
The pathogenesis and treatment of large granular lymphocyte leukemia. ( 24679833 )
2014
22
Lack of common TCRA and TCRB clonotypes in CD8(+)/TCRI+I^(+) T-cell large granular lymphocyte leukemia: a review on the role of antigenic selection in the immunopathogenesis of CD8(+) T-LGL. ( 24413066 )
2014
23
Concurrent administration of darbepoetin alfa, cyclosporine A, and prednisolone is useful for T cell large granular lymphocyte leukemia associated with myelodysplastic syndrome complicated by Coombs-negative hemolytic anemia. ( 24756696 )
2014
24
Distinct effect of cyclophosphamide and cyclosporine on pure red cell aplasia associated with T-cell large granular lymphocyte leukemia. ( 25466263 )
2014
25
T-Cell Large Granular Lymphocyte Leukemia in the Lower Eyelid. ( 25198396 )
2014
26
Submicroscopic genomic rearrangements change gene expression in T-cell large granular lymphocyte leukemia. ( 24649974 )
2014
27
Acquired inhibitors to factor VIII and fibrinogen in the setting of T-cell large granular lymphocyte leukemia: a case report and review of the literature. ( 25396761 )
2014
28
STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. ( 24350896 )
2013
29
Diagnosing large granular lymphocyte leukemia is bloody difficult. ( 23025294 )
2013
30
Large granular lymphocyte leukemia associated with hepatitis C virus infection and B cell lymphoma: improvement after antiviral therapy. ( 23176408 )
2013
31
Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia. ( 24014875 )
2013
32
T-cell large granular lymphocyte leukemia in a child with anemia and Crohn's disease. ( 23409990 )
2013
33
Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes. ( 24149287 )
2013
34
Familial CD3+ T Large Granular Lymphocyte Leukemia: Evidence that Genetic Predisposition and Antigen Selection Promote Clonal Cytotoxic T-Cell Responses. ( 24180333 )
2013
35
Long-term remission of T-cell large granular lymphocyte leukemia associated with rheumatoid arthritis after rituximab therapy. ( 23869084 )
2013
36
Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. ( 23515927 )
2013
37
Does IL-15 have a causative role in large granular lymphocyte leukemia? ( 23444952 )
2013
38
Peripheral blood immunophenotypic analysis as a diagnostic tool for large granular lymphocyte leukemia. ( 22938095 )
2013
39
Treatment of T-cell large granular lymphocyte leukemia with cyclosporine A: experience in a Chinese single institution. ( 23395383 )
2013
40
Large granular lymphocyte leukemia and lymphomatoid granulomatosis in the same patient: fortuitous association? ( 22799270 )
2013
41
Targeting IL-15 in large granular lymphocyte leukemia. ( 23634735 )
2013
42
Developing an in vitro model of T cell type of large granular lymphocyte leukemia. ( 24183305 )
2013
43
Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. ( 22830400 )
2012
44
Lymphocytosis: T-cell large granular lymphocyte leukemia. ( 23082329 )
2012
45
STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. ( 22859607 )
2012
46
Autoimmune manifestations in large granular lymphocyte leukemia. ( 22999943 )
2012
47
Asymptomatic T-cell large granular lymphocyte leukemia with an unusual immunophenotype. ( 24765467 )
2012
48
Large granular lymphocyte leukemia as a complication of rheumatoid arthritis. ( 22483660 )
2012
49
Extracorporeal photopheresis as a curative treatment strategy in non epidermotropic T-cell lymphoma and large granular lymphocyte leukemia. ( 22422944 )
2012
50
Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. ( 23153537 )
2012

Variations for Large Granular Lymphocyte Leukemia

Expression for Large Granular Lymphocyte Leukemia

Search GEO for disease gene expression data for Large Granular Lymphocyte Leukemia.

Pathways for Large Granular Lymphocyte Leukemia

Pathways related to Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.37 CSF2 IFNG IL2RA STAT3 STAT5B
2
Show member pathways
13.14 CSF2 IL2RA STAT3 STAT5B
3
Show member pathways
13.03 CSF2 IFNG IL2RA STAT3 STAT5B
4
Show member pathways
12.94 IFNG IL2RA STAT3 STAT5B
5 12.58 IFNG IL2RA STAT3 STAT5B
6
Show member pathways
12.55 IL2RA STAT3 STAT5B
7
Show member pathways
12.54 IFNG IL2RA STAT3 STAT5B
8
Show member pathways
12.36 IFNG STAT3 STAT5B
9
Show member pathways
12.3 IFNG IL2RA STAT3 STAT5B
10 12.25 IFNG IL2RA STAT3 STAT5B
11 12.2 CSF2 IL2RA STAT5B
12
Show member pathways
12.11 CSF2 IFNG STAT3
13
Show member pathways
12.08 IFNG STAT3 STAT5B
14
Show member pathways
12 IFNG STAT3 STAT5B
15
Show member pathways
11.86 IFNG STAT3 STAT5B
16
Show member pathways
11.85 IFNG IL2RA STAT3
17 11.78 CSF2 IFNG IL2RA
18
Show member pathways
11.74 IFNG IL2RA STAT3
19
Show member pathways
11.72 CSF2 IFNG IL2RA STAT3 STAT5B
20
Show member pathways
11.68 IFNG IL2RA STAT3 STAT5B
21 11.64 CSF2 IFNG
22 11.61 IFNG IL2RA
23 11.58 STAT3 STAT5B
24 11.58 CSF2 IFNG STAT5B
25 11.57 CSF2 IFNG
26 11.54 CSF2 IFNG
27
Show member pathways
11.53 CSF2 IFNG IL2RA
28
Show member pathways
11.51 IL2RA STAT5B
29 11.5 STAT3 STAT5B
30
Show member pathways
11.48 CSF2 IFNG
31
Show member pathways
11.46 IFNG IL2RA
32 11.44 IFNG STAT3
33 11.4 STAT3 STAT5B
34 11.4 IFNG IL2RA STAT3 STAT5B
35 11.37 STAT3 STAT5B
36 11.35 CSF2 STAT3
37 11.32 IFNG IL2RA
38
Show member pathways
11.27 STAT3 STAT5B
39
Show member pathways
11.25 STAT3 STAT5B
40 11.25 IL2RA STAT3 STAT5B
41 11.24 STAT3 STAT5B
42
Show member pathways
11.22 STAT3 STAT5B
43
Show member pathways
11.21 IL2RA STAT3 STAT5B
44 11.14 IFNG IL2RA
45 11.07 CSF2 IFNG
46
Show member pathways
11.03 IL2RA STAT5B
47 10.94 IFNG IL2RA STAT3
48 10.87 STAT3 STAT5B
49 10.69 CSF2 STAT3
50
Show member pathways
10.39 IFNG IL2RA STAT3 STAT5B

GO Terms for Large Granular Lymphocyte Leukemia

Biological processes related to Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.75 CSF2 IFNG IL2RA
2 positive regulation of gene expression GO:0010628 9.74 CSF2 IFNG STAT3
3 positive regulation of cell proliferation GO:0008284 9.67 CSF2 IFNG STAT3 STAT5B
4 cellular response to hormone stimulus GO:0032870 9.56 STAT3 STAT5B
5 positive regulation of erythrocyte differentiation GO:0045648 9.55 STAT3 STAT5B
6 interleukin-7-mediated signaling pathway GO:0038111 9.54 STAT3 STAT5B
7 regulation of multicellular organism growth GO:0040014 9.52 STAT3 STAT5B
8 T cell homeostasis GO:0043029 9.51 IL2RA STAT5B
9 JAK-STAT cascade GO:0007259 9.49 STAT3 STAT5B
10 positive regulation of activated T cell proliferation GO:0042104 9.48 IL2RA STAT5B
11 regulation of regulatory T cell differentiation GO:0045589 9.46 IFNG IL2RA
12 interleukin-15-mediated signaling pathway GO:0035723 9.43 STAT3 STAT5B
13 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.4 STAT3 STAT5B
14 interleukin-2-mediated signaling pathway GO:0038110 9.32 IL2RA STAT5B
15 interleukin-9-mediated signaling pathway GO:0038113 9.26 STAT3 STAT5B
16 positive regulation of interleukin-23 production GO:0032747 9.16 CSF2 IFNG
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.13 CSF2 IFNG STAT3
18 cytokine-mediated signaling pathway GO:0019221 8.92 CSF2 IL2RA STAT3 STAT5B

Molecular functions related to Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glucocorticoid receptor binding GO:0035259 8.62 STAT3 STAT5B

Sources for Large Granular Lymphocyte Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....